Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
40°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx, Inc. - Common Stock
(NQ:
ARDX
)
4.815
+0.215 (+4.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ardelyx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
July 13, 2023
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
June 29, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
June 05, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Recap: Ardelyx Q1 Earnings
May 03, 2023
Via
Benzinga
Earnings Preview For Ardelyx
May 02, 2023
Via
Benzinga
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
May 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 17, 2023
Gainers
Via
Benzinga
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/18
April 18, 2023
Via
Investor Brand Network
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 17, 2023
User Fee Goal Date: October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
May 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 09, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/13
April 13, 2023
Via
Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/5
April 05, 2023
Via
Investor Brand Network
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 4/3
April 03, 2023
Via
Investor Brand Network
7 High-Potential Penny Stocks in the Biotech Sector
May 04, 2023
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider.
Via
InvestorPlace
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
May 01, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
April 26, 2023
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Inc. (NASDAQ: ARDX) is a Stock Spotlight on 3/30
March 30, 2023
Via
Investor Brand Network
Ardelyx Earnings Perspective: Return On Capital Employed
March 07, 2023
Via
Benzinga
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
April 18, 2023
Company expects to receive goal review date in mid-May
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
April 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
April 12, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story
March 03, 2023
Via
Benzinga
3 Penny Stocks to Add to Your Watchlist for Potential Breakouts
April 11, 2023
These penny stocks are catching the attention of big-money investors as they continue to build up momentum for a potential breakout.
Via
InvestorPlace
7 A-Rated Stocks to Buy for April 2023
April 07, 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape.
Via
InvestorPlace
7 Core Stocks to Build a Solid Portfolio Around
March 13, 2023
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.
Via
InvestorPlace
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
March 03, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P...
Via
Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 03, 2023
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.